The purpose of this study is:
* To investigate whether the response to antipsychotic treatment can be enhanced by adding cannabidiol (CBD) to the existing treatment, compared to placebo, in participants with a first episode of psychosis, who have had a suboptimal or no response to their first antipsychotic treatment.
* To confirm the safety of CBD in people with psychosis.
The study is a randomized, double-blind, placebo-controlled, multi-centre, clinical trial. Individuals with a diagnosis of first-episode psychosis, who have had a suboptimal or no response to their first antipsychotic treatment will be recruited. These participants are randomised to treatment with CBD oral solution 500mg twice daily, or a matching placebo for 6 weeks, as an adjunct to their existing antipsychotic treatment. By using a battery of clinical outcome assessments, the trial will also assess several biomarkers to determine if they can be used to predict clinical outcomes and response to treatment with CBD. Biomarkers are being assessed as an exploratory outcome measure. Participants will be invited to provide blood and stool samples, and may be asked to complete neuroimaging assessments at certain eligible sites.

开始日期2025-04-01

申办/合作机构

University of Oxford

[+20]

ISRCTN17687131

/ RecruitingN/AIIT

Is Mindfulness for Adolescents and Carers plus treatment as usual more effective and cost-effective compared to treatment as usual alone; how does it work and for whom does it work best? A randomised controlled trial with embedded economic evaluation and study of mechanisms

开始日期2024-08-21

申办/合作机构

Cambridgeshire & Peterborough NHS Foundation Trust

ISRCTN86317609

/ CompletedN/AIIT

MELODIC: co-developing a Music therapy intervention Embedded in the Life Of Dementia Inpatient mental health Care to help manage distress

开始日期2023-10-01

申办/合作机构

University of Anglia Ruskin

[+1]

100 项与 Cambridgeshire & Peterborough NHS Foundation Trust 相关的临床结果

登录后查看更多信息

0 项与 Cambridgeshire & Peterborough NHS Foundation Trust 相关的专利（医药）

登录后查看更多信息

653

项与 Cambridgeshire & Peterborough NHS Foundation Trust 相关的文献（医药）

2025-06-01·Journal of Psychiatric Research

Pharmacological interventions and telomere length in patients with schizophrenia and bipolar disorder: A systematic review and meta-analysis

Review

作者: Sánchez-González, Juan Luis ; Vicente-Muñoz, Elsa ; Sánchez-Gil, Alba ; Martín-Vallejo, Javier ; Navarro-López, Víctor ; Perez, Jesus

BACKGROUNDPatients with schizophrenia and bipolar disorder have a life expectancy shorter than the general population. Cellular mechanisms underlying accelerated ageing, such as telomere shortening, may contribute to this premature mortality. We aimed to provide a comprehensive evaluation of the impact of pharmacological treatments for schizophrenia and bipolar disorder on telomere length.METHODPRISMA/MOOSE systematic review and meta-analysis from inception to June 2024. PubMed, Cochrane Library, SCOPUS, Web of Science, Embase and PsycInfo databases were searched for eligible studies. Methodological quality and risk of bias were evaluated with the Newcastle-Ottawa Scale and the Risk of Bias In Non-randomized Studies - of Exposure (ROBINS-E) respectively.RESULTSAn initial search retrieved 2133 articles. However, only 28 studies were finally included in qualitative synthesis and 19 in meta-analysis. All studies identified in the review were observational. Random-effects model analysis was used to quantify the difference in telomere length between cohorts of patients with schizophrenia or bipolar disorder and healthy control groups. The meta-analysis confirmed that telomere length was shorter in patients with schizophrenia (SMD = 0.35, 95 % CI 0.11 to 0.60; p=<0.0001) and bipolar disorder (SMD = 0.18, 95 % CI -0.04 to 0.39 p=<0.0001) than in healthy controls. This difference was not modified by predominant treatment with either lithium (SMD = 0.37, 95 % CI 0.04 to 0.69; p=<0.0001) or antipsychotics (SMD = 0.20, 95 % CI 0.02 to 0.38; p=<0.0001) at cohort level across studies.CONCLUSIONSPatients with schizophrenia or bipolar disorder have shorter telomeres than healthy populations. Predominant treatment with lithium or antipsychotics at cohort level did not have an impact on such shortening difference.REGISTRATIONPROSPERO CRD42024598840.

2025-05-01·BJPsych Open

Machine learning for prediction of childhood mental health problems in social care

Article

作者: Crowley, Ryan ; Rocheteau, Emma ; Parkin, Katherine ; Sippy, Rachel ; Massou, Efthalia ; John, Ann ; Friedmann, Yasmin ; Moore, Anna ; Liò, Pietro

BackgroundRates of childhood mental health problems are increasing in the UK. Early identification of childhood mental health problems is challenging but critical to children’s future psychosocial development. This is particularly important for children with social care contact because earlier identification can facilitate earlier intervention. Clinical prediction tools could improve these early intervention efforts.AimsCharacterise a novel cohort consisting of children in social care and develop effective machine learning models for prediction of childhood mental health problems.MethodWe used linked, de-identified data from the Secure Anonymised Information Linkage Databank to create a cohort of 26 820 children in Wales, UK, receiving social care services. Integrating health, social care and education data, we developed several machine learning models aimed at predicting childhood mental health problems. We assessed the performance, interpretability and fairness of these models.ResultsRisk factors strongly associated with childhood mental health problems included age, substance misuse and being a looked after child. The best-performing model, a gradient boosting classifier, achieved an area under the receiver operating characteristic curve of 0.75 (95% CI 0.73–0.78). Assessments of algorithmic fairness showed potential biases within these models.ConclusionsMachine learning performance on this prediction task was promising. Predictive performance in social care settings can be bolstered by linking diverse routinely collected data-sets, making available a range of heterogenous risk factors relating to clinical, social and environmental exposures.

2025-04-03·Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Spanish adaptation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS)

Article

作者: Radakovic, Ratko ; Salas Campos, Teresa ; Radakovic, Chelsea ; Rodríguez-Santos, Francisco ; Moran Benito, Yolanda ; Mascías Cadavid, Javier ; Marín Esteban, Saúl

Amyotrophic lateral sclerosis (ALS) is characterized functional decline, traditionally measured by the ALS Functional Rating Scale-Revised (ALSFRS-R). The Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) is an alternative comprehensive, detailed functional disability measure for people with ALS (pwALS), not yet translated to Spanish. The aim of this study was to translate and validate the Spanish ROADS. 53 Spanish speaking pwALS were recruited. They completed the ALSFRS-R and Spanish ROADS. Reliability (internal consistency, intra-class correlation) and validity (ALSFRS-R total and item-total correlations) were determined. The Spanish ROADS internal consistency reliability was excellent (Cronbach's standardized alpha = 0.94), the test-retest reliability intra-class correlation value was 0.93. There was a strong significant correlation between the Spanish ROADS and ALSFRS-R totals (r_s(52) = .89, p < .001). Additionally, the ALSFRS-R subscales and ROADS items correlations showed domain-to-item specific expected significant correlations. The Spanish ROADS is a psychometrically robust, valid and reliable measure for quantifying functional disability for pwALS.

100 项与 Cambridgeshire & Peterborough NHS Foundation Trust 相关的药物交易

登录后查看更多信息

100 项与 Cambridgeshire & Peterborough NHS Foundation Trust 相关的转化医学

登录后查看更多信息